Heart Test Laboratories (NASDAQ:HSCS) Given New $14.00 Price Target at Ascendiant Capital Markets

Heart Test Laboratories (NASDAQ:HSCS) had its price objective reduced by Ascendiant Capital Markets from $15.00 to $14.00 in a report released on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, Maxim Group reiterated a “buy” rating and issued a $12.00 target price on shares of Heart Test Laboratories in a report on Wednesday, December 18th.

Heart Test Laboratories Price Performance

Shares of NASDAQ:HSCS opened at $3.15 on Tuesday. Heart Test Laboratories has a 52 week low of $2.36 and a 52 week high of $13.50. The company has a market cap of $3.09 million, a P/E ratio of -0.40 and a beta of 2.77. The company has a quick ratio of 1.52, a current ratio of 1.72 and a debt-to-equity ratio of 0.01. The business has a fifty day simple moving average of $3.43 and a 200-day simple moving average of $3.43.

Heart Test Laboratories (NASDAQ:HSCS) last issued its earnings results on Thursday, March 13th. The company reported ($2.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.53) by ($0.04). Equities research analysts forecast that Heart Test Laboratories will post -10.01 EPS for the current year.

About Heart Test Laboratories

Heart Test Laboratories, Inc, a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals.